Foresite Capital Management II’s Larimar Therapeutics LRMR Stock Holding History

Foresite Capital Management II’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,565	Closed	-$108K	–	12
2017 Q3	$108K	Sell	2,565 -7,410	-74%	-$308K	0.04%	12
2017 Q2	$420K	Sell	9,975 -27,480	-73%	-$1.41M	0.19%	11
2017 Q1	$2.1M	Sell	37,455 -17,860	-32%	-$887K	0.9%	10
2016 Q4	$2.11M	Sell	55,315 -8,022	-13%	-$325K	1.06%	7
2016 Q3	$2.52M	Hold	63,337	–	–	1.2%	8
2016 Q2	$4.55M	Sell	63,337 -55,186	-47%	-$4.36M	3.11%	8
2016 Q1	$9.5M	Sell	118,523 -5,511	-4%	-$435K	4.65%	10
2015 Q4	$9.36M	Buy	124,034 +56,426	+83%	+$9.06M	3.14%	10
2015 Q3	$25.9M	Hold	67,608	–	–	7.87%	3
2015 Q2	$28.1M	Sell	67,608 -225,013	-77%	-$94.1M	9.86%	4
2015 Q1	$56.5M	Buy	292,621 +250,940	+602%	+$119M	33.47%	1
2014 Q4	$15.4M	Buy	+41,681	New	+$10.7M	10.56%	3

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Foresite Capital Management II's LRMR Position: Q4 2017 in Review

Foresite Capital Management II sold out of Larimar Therapeutics (LRMR) in Q4 2017, closing a stake of 2,565 shares — an estimated $108K sold.

Foresite Capital Management II first reported a position in LRMR in Q4 2014 and held it in 12 quarters. The position peaked at $56.5M in Q1 2015. 56 funds tracked by Wall St. Rank hold LRMR as of Q4 2017.

Foresite Capital Management II reported no remaining Larimar Therapeutics position as of Q4 2017 after selling out during the quarter.
Foresite Capital Management II sold 2,565 Larimar Therapeutics shares in Q4 2017, an estimated $108K.
Foresite Capital Management II first reported a position in Larimar Therapeutics in Q4 2014 and held it in 12 quarters.
Foresite Capital Management II's Larimar Therapeutics position peaked at $56.5M in Q1 2015.
56 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2017.

Based on Foresite Capital Management II's 13F filing for Q4 2017, filed 13 Feb 2018.